跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
A3-IS
首页
药物
A3-IS
A3-IS
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
CLEANING AGENT COMPOSITION
US 20260183221 A1
申请人: KAO CORP
优先权: 2022
CN
EP
US
WO
4 件公开
GLYCOSYLATED CYCLIC ENDOMORPHIN ANALOGS
EP 4531885 A4
申请人: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
优先权: 2022
EP
US
WO
4 件公开
Melanin production inhibitor
US 8846012 B2
申请人: YOKOYAMA KOUJI
优先权: 2008
EP
US
4 件公开
Polypeptides having anti-HIV activity and compositions comprising same
US 7138488 B2
申请人: BIOKINE THERAPEUTICS LTD
优先权: 2000
US
4 件公开
Alkoxy substituted imidazo[1,2-a]pyridines having affinity for amyloid
US 8303935 B2
申请人: TANIFUJI SHIGEYUKI
优先权: 2006
US
4 件公开
USE OF NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID, AND PROCESS FOR PRODUCTION OF THE SAME
US 2010267952 A1
申请人: NIHON MEDIPHYSICS CO LTD
优先权: 2007
CN
US
WO
3 件公开
US 2010249408 A1
申请人: NIHON MEDIPHYSICS CO LTD
优先权: 2007
CN
US
WO
3 件公开
US 2010216994 A1
申请人: NIHON MEDIPHYSICS CO LTD
优先权: 2007
CN
US
WO
3 件公开
UTILIZATION OF NOVEL COMPOUNDS WITH AMYLOID AFFINITY AND METHOD OF PRODUCING THE SAME
US 2010249419 A1
申请人: NIHON MEDIPHYSICS CO LTD
优先权: 2007
CN
US
WO
3 件公开
Complexes Of CU(I) As Antitumor Agents
US 2024239814 A1
申请人: UNIVERSITA´ DEGLISTUDI DI PADOVA
优先权: 2021
EP
US
WO
3 件公开
VECTORS TARGETING BETA-D-N-ACETYLGLUCOSAMINIDASE
US 2024424118 A1
申请人: CENTRE NAT RECH SCIENT
优先权: 2021
CN
US
WO
3 件公开
A3 ADENOSINE RECEPTOR LIGANDS FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH OCRL GENE DISFUNCTION
EP 4743089 A1
申请人: FOND TELETHON ETS
优先权: 2023
CN
EP
WO
3 件公开
第 1 / 10 页
上一页
下一页
药物
反馈